Cancer Immunotherapeutics and RNA-based Materials

Mini Symposium

Date/Time: Monday, July 22, 2019 - 1:30 PM to 3:30 PM
Log in to Add to My Schedule


Messenger RNA, or mRNA, could offer many advantages in gene therapy. It carries genetic information from DNA to ribosomes, where it instructs protein expression. It also has a limited lifetime, and unlike DNA, it isn’t permanently incorporated into a cell’s genome. Researchers and investors alike have become in love of some players in the mRNA field, many works from academia with really promising strategies as Dr Florindo and DeSmedt will present and most notably biotechs such as Moderna Therapeutics or BiOntech with an impressive pipeline in Cancer Immunotherapeutics. Nascent RNA immunotherapeutics include RNA vaccines encoding cancer neoantigens, mRNAs encoding immunomodulatory factors, viral RNA analogues, interference RNAs and protein-binding RNA aptamers. These approaches are already in early clinical development with promising safety and efficacy results.